Vg9Vd2 T cells have a natural inclination to recognize malignant B cells in vitro via receptors for stress-induced selfligands and TCR-dependent recognition of phosphoantigens (pAgs) generated in the mevalonate (Mev) pathway. This inclination is continuously challenged in vivo by the immune suppression operated by tumor cells. Multiple myeloma (MM) is a prototypic B-cell malignancy in which myeloma cells subvert the local microenvironment to reshape antitumor immune responses. In this study, we have investigated the immune competence of bone marrow (BM) Vg9Vd2 T cells in a large series of MM patients. We have found that the BM microenvironment significantly hampers the pAg-reactivity of BM Vg9Vd2 T cells, which become largely PD-1 C and are surrounded by PD-L1 C myeloma cells and increased numbers of PD-L1 C myeloid-derived suppressor cells (MDSC). Vg9Vd2 T-cell dysfunction is an early event that can be already detected in individuals with monoclonal gammopathy of undetermined significance (MGUS) and not fully reverted even when MM patients achieve clinical remission. Anti-PD-1 treatment increases the cytotoxic potential of Vg9Vd2 T cells by almost 5-fold after pAg stimulation, and appears to be a promising strategy for effective immune interventions in MM.
Introduction
Disease progression in MM depends on intrinsic myeloma cell features but also on the ability of myeloma cells to subvert the local microenvironment and reshape host immunity to support their growth, resistance to chemotherapy, and immune escape. 1 BM is the privileged site where myeloma cells continuously operate to escape antitumor immune surveillance. Vg9Vd2 T cells are non-conventional T cells halfway between innate and adaptive immunity with a natural inclination to react against malignant B cells, including myeloma cells. 2 They are equipped with a peculiar array of receptors for stress-induced self-ligands and a unique TCR-dependent recognition ability. Normally constituting only 1-5% of circulating T-cells in healthy adults, Vg9Vd2 T cells increase in microbial infections because they sense infectious agents via the TCR-dependent recognition of pAgs generated in the Mev and non-Mev pathway of microbial pathogens. Mammalian cells also generate pAgs, such as isopentenylpyrophosphate (IPP), which activate Vg9Vd2 T cells as efficiently as their natural ligands. 3, 4 Cell stress and transformation increase Mev activity and accelerate the formation of intracellular pAgs, whose accumulation in excess of physiological levels is sensed by Vg9Vd2 T cells.
IPP levels are increased by zoledronic acid (ZA) that selectively targets farnesyl-pyrophosphate synthase in the Mev pathway. 5 ZA stimulation can be used as a surrogate to interrogate the immune competence of Vg9Vd2 T cells. Approximately 50% of MM patients are anergic to ZA stimulation at diagnosis when this assay is performed in peripheral blood (PB) and monocytes are used to generate IPP. 6 This anergy is reversible if ZAtreated dendritic cells (DC), rather than monocytes, are used to stimulate PB Vg9Vd2 T cells, one possible explanation being that the former are better IPP producers. 7 We have previously shown in a limited series of patients that BM Vg9Vd2 T cells are also anergic to pAg stimulation, but the frequency and mechanisms underlying this dysfunction at the tumor site are unknown.
The aim of this study was to interrogate the immune competence of BM Vg9Vd2 T cells in a large series of MM patients and provide the groundwork to recover their antitumor effector functions.
Results

BM Vg9Vd2 T cells are more anergic to pAg stimulation than PB Vg9Vd2 T cells
In the first series of experiments, ZA-induced Vg9Vd2 T-cell proliferation was compared in PB and BM samples from MM patients at diagnosis (MM-dia). Vg9Vd2 T-cell frequencies were similar in BM and PB (data not shown) but both pooled and head-to-head data showed that total counts of viable Vg9Vd2 T cells were significantly higher in PB mononuclear cells (PBMC) than in BM mononuclear cells (BMMC) (Fig. 1A) . Since BM and PB samples are very different in terms of cell subset composition (Fig. 1B) , BMMC were also stimulated after immunomagnetic removal of myeloma cells without observing any recovery of Vg9Vd2 T-cell proliferation (Fig. 1C) .
Increased frequencies of BM and PB PMN-MDSC in MM patients
MDSC are increased in the BM and PB of MM patients, and suppress the proliferation of conventional T cells.
10 MDSC frequency was significantly higher in BM MM than BM control (CTRL), PB MM, and PB CTRL samples. PB MM also contained significantly higher MDSC percentages than PB CTRL samples ( Fig. 2A) . Polymorphonuclear MDSC (PMN-MDSC) and not monocytic MDSC (M-MDSC) were responsible for the increased MDSC frequency in MM as previously reported 10, 11 (see Table S1 for MDSC immunophenotype) (Fig. 2B) . Representative dot-plots of MDSC frequency in the BM and PB of MM and CTRL are shown in Fig. 2C .
ZACIL-2 stimulation was also carried out after depletion of MDSC without observing any recovery of BM Vg9Vd2 T-cell proliferation (Fig. 2D) . Since depletion was suboptimal and from 6% to 10% of MDSC were left in MM BM samples, ZACIL-2 stimulation was carried out in the presence of sildenafil, 1-methyl tryptophan (1-MT), N G -methyl-L-arginine acetate salt (L-NMMA), and apocynin (Fig. 2E) , but all inhibitors failed to reinstate ZA-induced Vg9Vd2 BM T-cell proliferation in MM patients. These inhibitors partially antagonized the suppressor activity exerted by MM BM MDSC against the anti-CD3/CD28-induced proliferation of PBT CTRL as previously reported (Fig. S1 ).
10
ZA-treated DC BM and DC PB effectively induce the proliferation of autologous PB but not of BM Vg9Vd2 T cells Next, we investigated whether ZA-treated DC generated from PB (DC PB ) or BM (DC BM ) CD14
C cells were able to reinstate Vg9Vd2
T-cell proliferation as previously reported in PB. 9 As expected, ZAtreated DC PB significantly reinstated PB Vg9Vd2 T-cell proliferation, but not that of BM Vg9Vd2 T cells (Fig. 3A) .
Cross-over experiments were performed in which ZA-treated DC BM and DC PB were generated from BM and PB CD14 C cells of the same patients and used to stimulate either autologous BM or PB Vg9Vd2 T cells (Fig. 3B) . ZA-treated DC PB and DC BM effectively induced the proliferation of PB Vg9Vd2 T cells but both failed to induce that of BM Vg9Vd2 T cells.
Anergy to pAg stimulation is disease-specific and not a general feature of BM-resident Vg9Vd2 T cells Next, we investigated whether the anergy of BM MM Vg9Vd2 T cells was not disease-related but, instead, caused by a Table S1 . PMN-MDSC were responsible for the increased MDSC frequency in the PB and BM of MM patients. Statistically significant differences are marked with symbols (always P < 0.001). distinct activation and/or differentiation state peculiar to the BM localization. Vg9Vd2 T cells are subcategorized according to their phenotype, proliferative capacity, migratory propensity, and effector functions [naive, central memory (CM), effector memory (EM), and terminally differentiated (TEMRA) subsets], but the distribution of these subsets was similar in MM and CTRL BM samples (Fig. S2) .
Bromohydrin-pyrophosphate (BrHPP) was also used to challenge the intrinsic pAg reactivity of MM and CTRL BM Vg9Vd2 T cells (Fig. 3C) . BrHPP is a synthetic IPP analog, which directly binds TCR and induces Vg9Vd2 T-cell proliferation in the absence of accessory cells, such as monocytes or DC. 12 The results shown in Fig. 3C clearly indicate that CTRL BM Vg9Vd2 T cells are fully reactive to ZA-and/or BrHPPinduced stimulation, whereas both stimulations are ineffective in MM BMMC.
BM Vg9Vd2 T-cell proliferation is not reinstated by neutralizing Tregs
We have recently shown that the BM of MM patients is steadily inhabited by a normal-sized pool of fully functional regulatory T cells (Tregs), 13 and the latter have been reported to suppress PB Vg9Vd2 T-cell proliferation.
14 Hence, MM BMMC were stimulated with ZACIL-2 in the presence of OX-40L or anti-TGF-b to inhibit the suppressor activity of Tregs, 15 but both treatments were unable to reinstate BM Vg9Vd2 T cell proliferation ( Fig. 4A and B) .
A final set of experiments was performed in which MM BMMC, BM lymphocytes (BML), purified BM T (BMT) cells, and BMT cells depleted of Tregs (BMT CD25¡ ) were stimulated with BrHPP and IL-2 but Vg9Vd2 T-cell proliferation was never recovered even after depletion of Tregs in BMT CD25¡ cultures (Fig. 4C ).
Vg9Vd2 T cells are PD-1
C in the BM of MM patients MM BM Vg9Vd2 T cells showed the highest PD-1 expression compared with Vg9Vd2 T cells from all other sources (Fig. 5A) . PD-1 expression was significantly higher in CM Vg9Vd2 T cells, which is the subset with the highest proliferative capacity (Fig. 5B) . MM BM Vg9Vd2 T cells were also the only cells to significantly upregulate PD-1 expression after ZA stimulation (Fig. 5C ).
Increased PD-L1 expression in myeloma cells and MM BM MDSC Next, we investigated whether the BM of MM patients was cohabited by PD-L1
C cells that could potentially engage PD-1 C Vg9Vd2 T cells. The majority of myeloma cells (>60%), 16 and a significant proportion of MDSC (>30%) were PD-L1
C in the BM of MM patients (Fig. 5D ). MM BM MDSC showed the highest PD-L1 expression, while MM PB MDSC were inclined to have higher PD-L1 expression than CTRL PB and BM MDSC, but the difference was not statistically significant. Representative dot-plots of PD-L1 expression in myeloma cells and MDSC from the BM of MM patients are shown in 
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Anti-PD-1 treatment partly reinstates MM BM Vg9Vd2 T-cell reactivity to pAg stimulation ZA stimulation was carried out in the presence of increasing anti-PD-1 mAb concentrations and a partial recovery of BM Vg9Vd2 T-cell proliferation was documented ( Fig. 5F and Fig. S3 ). To determine whether PD-1 neutralization also improved the cytotoxic capacity, we evaluated CD107 expression on Vg9Vd2 T cells after ZA stimulation in the presence of anti-PD-1 mAb. Data reported in Fig. S4 shows that there is a direct correlation between ZA-induced Vg9Vd2 T-cell proliferation and CD107 expression. According to the higher proliferative response, the frequency of CD107 C cells and the number of CD107 molecules per cell were significantly higher in CTRL than in MM BM Vg9Vd2 T cells after ZA stimulation (Fig. 6A) , but anti-PD-1 treatment significantly increased the frequency of CD107 C Vg9Vd2 T cells and the number of CD107 molecules per cell in ZA-stimulated MM BMMC, whereas isotype control was totally ineffective (Fig. 6B and Fig. S3 ).
Defective pAg-reactivity is an early and long-lasting MM BM Vg9Vd2 T-cell immune dysfunction ZA stimulation was carried out in BMMC from MGUS, MM in remission (MM-rem), MM in relapse (MM-rel), and compared with MM-dia values. Data from two patients with solitary extra-medullary plasmocytoma (SEP) are also shown in Fig. 7A . Anergy to pAg stimulation was already present in MGUS and similar to that of MM-dia, MM-rem, and MM-rel, whereas BM Vg9Vd2 T cells from SEP responded to ZA stimulation (Fig. 7A) .
PD-1 expression in Vg9Vd2 T cells was also similar in MGUS, MM-dia, and MM-rem, whereas MM-rel showed significantly higher values than MM-dia (Fig. 7B) .
Lastly, the frequency of MDSC and PD-L1 expression in MDSC were also compared. MM-rem showed a significantly increased frequency of MDSC, compared with MM-dia and MM-rel (Fig. 7C) , whereas no differences were observed between MGUS, MM-dia, and MM-rel. Similar proportions of MDSC were PD-L1
C in MM-dia, MM-rem, and MM-rel (Fig. 7D ).
Discussion
Our results confirm that the immune contexture in the BM of MM patients is highly suppressive and that BM Vg9Vd2 T cells are more dysfunctional than PB Vg9Vd2 T cells when challenged head-to-head by pAgs in individual patients. Removal of myeloma cells, MDSC or Tregs, or the functional inhibition of MDSC and Tregs were insufficient to reinstate MM BM Vg9Vd2 T-cell pAg reactivity. Gorgun et al. 10 have also reported that functional inhibition of BM-derived MDSC is insufficient to recover the reactivity of autologous T cells to anti-CD3/CD28 stimulation.
The cross-over experiments clearly showed that defective pAg reactivity is peculiar to MM BM Vg9Vd2 T cells, which do not proliferate no matter whether they are stimulated with BM-or PB-derived ZA-treated DC. Conversely, both BM-and PBderived ZA-treated DC induced the proliferation of PB Vg9Vd2 T cells.
Defective pAg reactivity is not a general feature of BM-resident Vg9Vd2 T cells. The distribution of Vg9Vd2 T-cell subsets with low proliferative capacity (i.e., EM and TEMRA cells) was similar in MM and CTRL BM, and BM Vg9Vd2 T cells from CTRL and two patients with SEP, devoid of myeloma cells, efficiently proliferate in response to ZA or BrHPP stimulation. The latter is a synthetic pAg that does not require either monocytes or DC to activate Vg9Vd2 T cells. 12 Altogether, these data indicate that defective pAg reactivity is mainly imputable to Vg9Vd2 T cells and specifically restricted to MM patients with BM myeloma cell infiltration.
PD-1 expression was significantly increased in MM BM Vg9Vd2 T cells. Increased PD-1 expression has been reported in PB NK cells 17 and T cells 1820 of MM patients, but this is the first report that show increased PD-1 expression in immune effector cells at the tumor site. To date, PD-1 expression at the tumor site has only been reported in the 5T33 murine model of myeloma in which spleen and BM-derived CD4
C and CD8 C cells were reported to be PD-1 C , to have an exhausted phenotype, 20 and to include tumor-specific T cells. 21 These results indicate that the immune suppressive mechanisms operated by myeloma cells and bystander cells in the tumor microenvironment are able to induce PD-1 expression on both adaptive and innate immune effector cells.
Interestingly, PD-1 expression was predominant in CM Vg9Vd2 T cells, which have the highest proliferative response to pAg stimulation, 22 and further increased after ZA stimulation. These data indicate that MM BM Vg9Vd2 T cells are prone to further upregulate the expression of immune checkpoint receptors upon ineffective TCR engagement by pAgs.
Very little is known about the expression and function of PD-1 in Vg9Vd2 T cells. Iwasaki et al. 23 analyzed PD-1 expression in PB Vg9Vd2 T cells after pAg stimulation in CTRL and one breast-cancer patient. They found that PD-1 C Vg9Vd2 T cells produced less IFNg, showed lower cytotoxic activity and CD107 degranulation than PD-1 ¡ Vg9Vd2 T cells when challenged with PD-L1
C tumor target cells. 23 We have shown that the MM BM microenvironment is abundantly inhabited by PD-L1 C cells. We have confirmed that the majority of myeloma cells are PD-L1 C16,18 but we have found that a significant proportion of MDSC are also PD-L1
C . This is the first report showing PD-L1 expression in human MDSC at also Table S1 ). CM Vg9Vd2 T cells showed significantly higher PD-1 expression than all other subsets. Statistically significant differences are marked with symbols (*P < 0.001; P < 0.001; P D 0.001). 
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Volume 4 Issue 11 OncoImmunology the tumor site. Interestingly, PD-L1 expression in MM was significantly higher in BM than PB MDSC, whereas no difference was observed between PB and BM in CTRL. This may explain why Favaloro et al. 24 who investigated only PB samples did not find any significant PD-L1 expression in MDSC of MM patients.
The BM microenvironment is highly hypoxic in MM, 25 and it has recently been shown that hypoxia induces PD-L1 upregulation in splenic MDSC from tumorbearing mice, but not in MDSC from peripheral lymphoid organs not infiltrated by tumor cells. 26 Interestingly, Myklebust et al. 27 have shown that histiocytes are PD-L1
C and deliver negative signals to bystander T cells, which are PD-1 C , in the lymph nodes of follicular lymphoma patients. Altogether, these data indicate that immune responses at the tumor site are blunted by direct interactions with tumor cells, but also by the tumor-induced recruitment of immune suppressive bystander cells and vice versa, as shown by the ability of BMSC to induce PD-L1 expression on myeloma cells. 28 Previous reports have shown that PD-1 blockade enhances in vitro T-cell responses to autologous dendritic/myeloma fusion vaccines 17 and to the NK cell-mediated killing of autologous myeloma cells. 18 In the 5T33 murine myeloma model, PD-L1 blockade in combination with myeloma cell vaccination and autologous transplantation increased the survival of myelomabearing mice, 20 while PD-L1 blockade in combination with lymphopenia induced by non-myeloablative irradiation resulted in the elimination of 5T33 myeloma cells both in the spleen and the BM. 21 We achieved an almost 2-fold proliferative response of BM Vg9Vd2 T cells to ZA stimulation in the presence of anti-PD-1 mAb. The increased proliferation was matched by increased cell surface CD107 mobilization implying an improved cytotoxic activity of MM BM Vg9Vd2 T cells. By combining the increased number of Vg9Vd2 T cells, the increased frequency of CD107 C Vg9Vd2 T cells, and the increased number of CD107 molecules per cell, the cytotoxic potential of Vg9Vd2 T cells increased by almost 5-fold after ZA stimulation in the presence of anti-PD-1 mAb. An increased effector to target ratio is highly desirable in immunotherapy, and we have previously shown that Vg9Vd2 T cell ability to kill myeloma cells is indeed limited by the proportion of tumor target cells. 6 The apparent discrepancy between the removal of PD-L1 C cells, such as myeloma cells or MDSC, and the unsuccessful recovery of ZA-induced Vg9Vd2 T-cell proliferation can be explained by the tonic signaling operated by PD-1 even in the absence of engagement by PD-L1 and PD-L2. In tumor-infiltrating lymphocytes, which resemble MM BM Vg9Vd2 T cells, PD-1 expression is maintained irrespective of PD-L1 or PD-L2 engagement provided that the TCR is continuously engaged, whereas PD-1 expression fades away if TCR stimulation is interrupted. 29 Youngblood et al. 30 have shown that PD-1 expression is regulated by the methylation status of the PDCD1 region. In chronic viral infections, the PDCD1 regulatory region remains demethylated in functionally exhausted PD-1 C CD8 C cells. The lack of remethylation is a consequence of sustained viral exposure that exceeds the restricted timeframe for PDCD1 remethylation, and PD-1 downregulation. 30 Further evidence about negative PD-1 tonic signaling was provided by Benson et al. 17 who showed in MM patients that a prolonged pre-incubation with anti-PD-1 mAb and IL-2 is necessary to improve the cytotoxic capacity of NK cells, whereas a short incubation period just before mixing NK cells with myeloma cells to merely interrupt PD-1/PD-L1 interactions is ineffective.
To build on the hypothesis that MM BM Vg9Vd2 T cells have become PD-1 C as a consequence of a prolonged TCR engagement, we investigated IPP production in myeloma cells and BMSC. Preliminary results indicate that MM BMSC produce and release very high amounts of IPP, whereas CTRL BMSC do not (Fig. S5) . These data suggest that the BM microenvironment is abundantly repleted with pAgs that can engage Vg9Vd2 T cells. This engagement occurs within an immune suppressive microenvironment under adverse conditions in terms of costimulatory signals and/or cytokines leading to the functional exhaustion of Vg9Vd2 T cells.
Vg9Vd2 T-cell dysfunction is an early event during evolution of the disease, and does not fade away in clinical remission. This finding was unexpected because the current opinion is that the immune competence of MGUS individuals is preserved. 31 NKT cells, another subset of unconventional T cells sharing several Vg9Vd2 T-cell characteristics, have been reported to be immune competent in MGUS, but to become dysfunctional once the disease progresses to active MM. 32 PD-1 expression was already present on BM Vg9Vd2 T cells from MGUS and remained upregulated in MM-rem. Significantly higher PD-1 expression was only observed in BM Vg9Vd2 T cells from MM-rel. Rosenblatt et al. 18 reported that PD-1 expression on T cells returned to CTRL levels in MM patients in complete remission after autologous transplantation. This discrepancy probably reflects the different cell types investigated (T cells vs. Vg9Vd2 T cells) and, especially, the different cell sources of investigation (PB vs. BM).
MDSC frequency too was similar in MGUS, compared with MM-dia and MM-rel, whereas it was significantly higher in MM-rem, compared with MMdia and MM-rel. No correlation was found between myeloma cells and BM MDSC frequencies in individual patients. Ramachandran et al. 11 too did not find any correlation between myeloma cell infiltration and the frequency of BM MDSC. They showed in a mouse model that MDSC starts to accumulate in BM as early as one week after tumor inoculation when the frequency of myeloma cells in the BM is lower than 10% as in MGUS individuals. 11 Hence, the tumor burden per se is not the major drive to induce BM MDSC accumulation.
Interestingly, MDSC remain PD-L1
C also in MM-rem, indicating that the PD-1/PD-L1 pathway is still operative and can suppress Vg9Vd2 T-cell immune function even when the majority of myeloma cells have been cleared from BM. Our results are consistent with those reported by Zheng et al. 33 who showed that the homeostasis of systemic cytokines is already unbalanced in MGUS individuals and does not return to normality after treatment. BM Vg9Vd2 T-cell immune dysfunction already present in MGUS may explain why the administration of ZA in high-risk MGUS and smoldering myeloma decreased the frequency of bone lesions, but not the transition rate to MM, 34 and why the clinical trials that have used ZA or other pAgs to intentionally activate Vg9Vd2 T cells in vivo or ex vivo have fallen short of clinical expectations even when patients were selected based on the in vitro reactivity of PB Vg9Vd2 T cells to pAg stimulation. 35, 36 Our results may help to develop more effective immune interventions in MM. The persistence of PD-1 C Vg9Vd2 T cells indicate that anti-PD-1 treatment can be beneficial to unleash the effector functions not only of Vg9Vd2 T cells, but also of NK cells and T cells. Anti-PD-1 treatment can be combined with other strategies, such as pAg-induced Vg9Vd2 T-cell activation, tumor vaccination 17 and lymphodepletion. 21 The persistence of PD-L1 C MDSC can also hinder the efficacy of immunotherapy during remission. Drugs, such as bortezomib or lenalidomide, are currently used for consolidation or maintenance treatments but they have no effect on the frequency and suppressor activity of MDSC. 11 The finding that MDSC are 
PD-L1
C raises the possibility of targeting these cells with anti-PD-L1 mAb and eventually interrupting the negative signaling performed by the PD-1/PD-L1 pathway.
Lastly, our findings provide the rationale to explore immune checkpoint neutralization and Vg9Vd2 T-cell activation as nongenotoxic approaches to boost anti-myeloma immune surveillance in high-risk MGUS.
Materials and Methods
Patients
One-hundred and forty six MM patients and ten subjects with MGUS entered the study. The MM series included 70 MM-dia, 52 MM-rem, and 24 MM-rel patients. BM and PB were investigated head-to-head in 13 MM cases at diagnosis. The control group (CTRL) included 28 PB samples from healthy blood donors, kindly provided by the local Blood Bank and Transfusion Service, 3 BM samples from individuals undergoing postdegenerative or post-traumatic hip prosthesis implantation at the local Traumatology and Orthopaedic Centre, and 15 frozen human bone marrow mononuclear cell (BMMC) samples purchased from Stem Cells Technologies (Vancouver, Canada).
The study was approved by the local Institutional Review Board (DN 2012/388) and samples collected after the written informed consent was obtained.
Immunophenotyping Myeloma cells, Vg9Vd2 T cells and subsets (na€ ıve, CM, EM, and TEMRA), MDSC and subsets (PMN-MDSC and M-MDSC), bone marrow stromal cells (BMSC), and Tregs were immunophenotyped in BM and PB samples from MM and CTRL as reported in the Table S1 .
Vg9Vd2 T-cell activation and proliferation PBMC and BMMC were incubated for 7 d with 10 IU/mL IL-2 (Eurocetus, Milan, Italy) and 1 mM ZA (Novartis Pharma) as previously reported. 6 In selected experiments, 3 mM BrHPP (kindly provided by Innate Pharma) was used to stimulate PB and BM Vg9Vd2 T cells. Total counts of viable Vg9Vd2 T cells and CD107 expression on Vg9Vd2 T cells were evaluated as previously reported. 6, 8 Vg9Vd2 T-cell proliferation and CD107 expression were also evaluated after stimulation of PBMC and BMMC in the presence of anti-PD1 mAb or isotype control (R&D Systems, Minneapolis, USA).
Vg9Vd2 T-cell stimulation by ZA-treated DC ZA-treated DC were generated from CD14 C cells isolated from PB or BM samples and used to stimulate autologous PBL/ BML or PBT/BMT, as previously reported. 9 Total counts of viable Vg9Vd2 T cells were calculated on day 7 as reported above.
MDSC and Tregs inhibition and depletion BMMC were cultured for 7 d with IL-2 and ZA in the absence or presence of 50 mg/mL sildenafil, 1 mM 1-MT, 500 mM L-NMMA, and 100 mM apocynin (all from Sigma Aldrich, Milan, Italy) to inhibit phosphodiesterase-5 (PDE5), indoleamine-2, 3-dyoxigenase (IDO), inducible nitric oxide synthase (iNOS), and reactive oxygen species (ROS), respectively. In depletion experiments, MDSC were removed from BMMC by immunomagnetic separation using a cocktail of CD33/CD11b/CD15-coated microbeads (Miltenyi Biotech, Bologna, Italy).
To test the role of Tregs, BMMC were cultured for 7 d with ZACIL-2 in the absence or presence of 100 ng/mL soluble recombinant human OX40L (R&D Systems) or 50 ng/mL soluble recombinant human anti-TGF-b (Life Span Biosciences, Seattle, WA).
BrHPP and IL-2 were also used to stimulate BMMC, CD14-depleted BMMC (BML), purified BM T cells (BMT), and CD25-depleted BM T cells (BMT CD25¡ ) for 7 d.
Statistical analysis
The results are expressed as mean §SE. Differences between groups were evaluated with the Wilcoxon-Mann-Whitney nonparametric test for paired or unpaired samples, as appropriate, and considered statistically significant for P values <0.05. Correlation analyses were performed with the non-parametric Spearman Rank Order test with a cut-off P value <0.05. The SigmaStat software (Systat Software Inc.. Richmond, USA) was used for statistical analyses.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. the revision of the final draft and approved the manuscript submission.
Supplemental Material
Supplemental data for this article can be accessed on the publisher's website.
